It was found that found that melanoma patients who responded to PD-1 had higher levels of B5 in their plasma than patients who did not respond to PD-1, providing further evidence of the impact that Vitamin B5 has in improving response to PD-1 immunotherapies (54). This evidence concerns the gene PDCD1 and melanoma.